Michiaki Takahashi

Summary

Country: Japan

Publications

  1. ncbi Development of varicella vaccine
    Michiaki Takahashi
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
    J Infect Dis 197:S41-4. 2008
  2. ncbi Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts
    Kimiyasu Shiraki
    Department of Virology, Toyama Medical and Pharmaceutical University, Toyama, Japan
    J Infect Dis 188:1875-7. 2003
  3. ncbi Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay
    Michiaki Takahashi
    Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan
    Vaccine 21:3845-53. 2003
  4. ncbi Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factor
    Yuka Hama
    Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    J Virol 84:1616-24. 2010
  5. ncbi Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus
    Shigefumi Okamoto
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan
    Clin Vaccine Immunol 19:17-22. 2012
  6. ncbi Varicella-zoster virus ORF 58 gene is dispensable for viral replication in cell culture
    Hironori Yoshii
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Osaka, Japan
    Virol J 5:54. 2008
  7. ncbi DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine
    Yasuyuki Gomi
    Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, 2 9 41, Yahata cho, Kanonji, Kagawa, Japan
    Vaccine 26:5627-32. 2008
  8. ncbi Effectiveness of live varicella vaccine
    Michiaki Takahashi
    The Research Foundation for Microbial Diseases, Osaka University, Osaka, Japan
    Expert Opin Biol Ther 4:199-216. 2004
  9. ncbi Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli
    Kazuhiro Nagaike
    Department of Microbiology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    Vaccine 22:4069-74. 2004
  10. ncbi Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography
    Takeshi Tanimoto
    Laboratory of Prevention of Viral Disease (Research Foundation for Microbial Diseases of Osaka University, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan
    Vaccine 23:4598-609. 2005

Collaborators

Detail Information

Publications14

  1. ncbi Development of varicella vaccine
    Michiaki Takahashi
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
    J Infect Dis 197:S41-4. 2008
    ..3%] of 260 vs. 12 [17.1%] of 70, respectively). Because of the pathogenesis of VZV, the incidence of latency and of HZ is predicted to be lower among vaccine recipients than among individuals who have experienced varicella...
  2. ncbi Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts
    Kimiyasu Shiraki
    Department of Virology, Toyama Medical and Pharmaceutical University, Toyama, Japan
    J Infect Dis 188:1875-7. 2003
    ..The high affinity to hepatocytes and lung fibroblasts might correlate with varicella hepatitis and pneumonia and with autopsy observations of varicella. Cell tropism may be important in understanding the pathogenesis of VZV...
  3. ncbi Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay
    Michiaki Takahashi
    Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan
    Vaccine 21:3845-53. 2003
    ..Although this study was uncontrolled open study, the results suggest that administering live varicella vaccine to the elderly is effective for enhancing immunity, particularly CMI to VZV...
  4. ncbi Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factor
    Yuka Hama
    Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    J Virol 84:1616-24. 2010
    ..The intrathecal production of anti-IE62 antibody augmenting BDNF activity and peripheral nerve injury by zoster may participate in the pathogenesis of allodynia in zoster...
  5. ncbi Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus
    Shigefumi Okamoto
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan
    Clin Vaccine Immunol 19:17-22. 2012
    ....
  6. ncbi Varicella-zoster virus ORF 58 gene is dispensable for viral replication in cell culture
    Hironori Yoshii
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Osaka, Japan
    Virol J 5:54. 2008
    ..In order to clarify whether ORF58 is essential for the growth of VZV, we constructed a deletion mutant of ORF58 (pOka-BACDelta58) from the Oka parental genome cloned into a bacterial artificial chromosome (pOka-BAC)...
  7. ncbi DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine
    Yasuyuki Gomi
    Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, 2 9 41, Yahata cho, Kanonji, Kagawa, Japan
    Vaccine 26:5627-32. 2008
    ..We also provide evidence that a nonsynonymous substitution at position 105356 may affect viral replication in vivo...
  8. ncbi Effectiveness of live varicella vaccine
    Michiaki Takahashi
    The Research Foundation for Microbial Diseases, Osaka University, Osaka, Japan
    Expert Opin Biol Ther 4:199-216. 2004
    ..A clear answer is difficult to give at present, although, for several reasons, such situations may be unlikely to occur...
  9. ncbi Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli
    Kazuhiro Nagaike
    Department of Microbiology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    Vaccine 22:4069-74. 2004
    ..The resulting recombinant rV02 grew as well as the parental virus in HEL cells. The recombinant VZV will promote VZV research and increase use of the viral genome as an investigative tool...
  10. ncbi Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography
    Takeshi Tanimoto
    Laboratory of Prevention of Viral Disease (Research Foundation for Microbial Diseases of Osaka University, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan
    Vaccine 23:4598-609. 2005
    ..4- to 1.6-fold higher than that in the corresponding viral particles. They also suggest that the NA content can be estimated by the immunochoromatography technique using anti-viral NA mAbs...
  11. ncbi Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine
    Pranee Somboonthum
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7 6 8 Saito Asagi, Ibaraki, Osaka 567 0085, Japan
    Vaccine 25:8741-55. 2007
    ..Therefore, the novel varicella vaccine expressing MuV HN protein is suitable as a polyvalent live attenuated vaccine against VZV and MuV infections...
  12. ncbi The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation
    Mark Quinlivan
    Department of Medical Microbiology, School of Medicine, Queen Mary College, London, United Kingdom
    J Infect Dis 186:888-94. 2002
    ..We used the BglI site to examine both the spread of type A viruses in the United Kingdom and the patterns of VZV infections within persons from different ethnic groups who grew up in the United Kingdom or abroad...
  13. ncbi Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus
    Yasuyuki Gomi
    Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan
    J Virol 76:11447-59. 2002
    ..Furthermore, the Oka vaccine virus was completely distinguishable from P-Oka and 54 clinical isolates by seven restriction-enzyme fragment length polymorphisms that detected differences in the DNA sequence...
  14. ncbi Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus
    Hironori Yoshii
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7 6 8, Saito Asagi, Ibaraki, Osaka 567 0085, Japan
    Vaccine 25:5006-12. 2007
    ..This is the first report that the vOka genome was cloned into BAC vector. The rvOka-BAC system would be useful as a vector for construction of recombinant live vaccines...